Skip to main content
. 2012 May 11;67(9):2139–2142. doi: 10.1093/jac/dks173

Figure 1.

Figure 1.

RG-tenofovir (TFV) gel and the original TFV gel effects on tissue viability and protection from HIV-1 challenge. (a) The effect of RG-TFV gel and original TFV gel on viability of polarized colorectal and ectocervical explant cultures. Duplicate polarized colorectal and ectocervical explant cultures were treated overnight with 1 : 5 dilutions of RG-TFV, original TFV or Gynol II (2% N9-containing) gels. Untreated explants were used as the reference control for each tissue. After product exposure, explants were washed and placed in medium containing MTT to evaluate mitochondrial activity. The data shown are the mean ± SD from a minimum of three independent tissues. (b) Anti-HIV-1 activity of the RG-TFV and original TFV gels were determined using colorectal and ectocervical (c) explant cultures. After overnight exposure to HIV-1 with or without either gel, the explant cultures were washed and followed for 21 days. Supernatant was collected and replenished every 3–4 days and used for HIV-1 p24 analysis by ELISA. The data shown are the median ± 95% CI of a minimum of three independent colorectal and ectocervical tissues.